A New Vision: AVD-104 Redefines Hope for Macular Degeneration

CAMBRIDGE, MA – December 15, 2025 – In the complex world of biotechnology, clinical trial results are often reduced to a simple binary: success or failure. But for the millions living under the shadow of geographic atrophy (GA), an advanced and irreversible form of age-related macular degeneration (AMD), the recent news from Aviceda Therapeutics requires a look far beyond the initial headline. While the company’s investigational therapy, AVD-104, did not meet its primary statistical goal against an active competitor in a Phase 2b study, the deeper story reveals a potential paradigm shift in how we treat this leading cause of blindness.

The results from the SIGLEC trial showcase an innovative therapy that not only slows the disease’s relentless march but, in a remarkable departure from existing treatments, also demonstrates the potential to grant patients sustained gains in visual acuity. This development represents more than just promising data; it signals a dedicated investment in a future where treatment moves beyond mere maintenance to meaningful restoration, offering a tangible new form of hope to a community in desperate need.

Decoding the Data Beyond the Primary Endpoint

The top-line announcement from Aviceda stated that AVD-104 did not show a statistically significant difference in slowing the growth of GA lesions compared to avacincaptad pegol (Izervay), one of two FDA-approved therapies. However, the company attributed this outcome to "imbalances in key baseline lesion characteristics across treatment arms." In clinical research, this is a critical detail. It suggests that the groups of patients receiving the different treatments may not have started from an equivalent point of disease severity, making a direct head-to-head comparison challenging and potentially masking the true effect of the new therapy.

When viewed against a different, and arguably more fundamental, benchmark—the natural, untreated progression of the disease—AVD-104’s performance was striking. The study showed that monthly treatment with AVD-104 resulted in an approximately 31% reduction in the rate of lesion growth compared to historical data from untreated (sham) patient groups. This level of reduction is clinically meaningful and falls squarely in the range of efficacy that led to the approval of the current complement-inhibiting therapies, pegcetacoplan (Syfovre) and avacincaptad pegol, in their own pivotal trials against sham controls.

This context is vital. While failing to outperform an active drug is a setback, demonstrating strong efficacy against the disease's natural course validates the drug's fundamental activity and provides a strong rationale for its continued development.

A True Innovation: Modulating the Immune Response

What truly sets AVD-104 apart is its mechanism of action, a novel approach that represents a significant innovation in the field. The two currently approved treatments for GA work by inhibiting the complement system, a part of the body's innate immunity that can become overactive and drive inflammation in the retina. While effective at slowing damage, this approach is akin to building a dam to hold back a flood.

Aviceda’s AVD-104, a sialic acid-coated nanoparticle, takes a more nuanced approach. It is a "glyco-immune checkpoint therapy" that directly engages with and modulates the behavior of the immune system’s frontline soldiers: macrophages and microglia. These cells are known to contribute to the inflammatory environment that destroys retinal tissue in GA. AVD-104 binds to specific receptors on these cells, known as SIGLECs, effectively instructing them to stand down, reduce pro-inflammatory activity, and restore balance. This is less like building a dam and more like calming the storm itself.

"The SIGLEC study represents the first clinical validation of glycoimmune checkpoint therapy to modulate macrophages and microglia to treat geographic atrophy," said Jeffrey Nau, PhD, MMS, Chief Executive Officer of Aviceda Therapeutics. "These results reinforce our belief that AVD-104 can provide meaningful functional vision benefit while reducing lesion progression."

The Unprecedented Promise of Functional Vision Gain

For patients, the most profound finding from the SIGLEC trial is the one that directly impacts their daily lives: vision. In a result described as not having been observed in other major GA clinical trials to date, patients treated monthly with AVD-104 experienced a sustained improvement in their best-corrected visual acuity (BCVA). While the average gain of +0.6 letters at 12 months may seem small, in a disease characterized by relentless vision loss, any stabilization—let alone improvement—is a monumental achievement.

Furthermore, nearly 29% of participants gained five or more letters of vision, with almost 17% gaining ten or more. This is the difference between seeing a loved one's face more clearly or being able to read another line on a chart. Existing therapies have succeeded in slowing the anatomical progression of GA, but they have not demonstrated this kind of functional benefit. They help patients keep the vision they have for longer, but AVD-104 hints at the possibility of getting some back.

This functional improvement is coupled with a highly encouraging safety profile. A major concern with current complement inhibitors is an increased risk of conversion to neovascular or "wet" AMD (nAMD), a complication that requires its own separate treatment and can cause rapid, severe vision loss. The SIGLEC trial reported a low nAMD conversion rate of just 2% in the AVD-104 arm, with no instances of drug-related serious adverse events like retinal vasculitis.

"We are encouraged by the magnitude of visual acuity gains, including protection from significant vision loss... and the compelling safety profile observed with monthly AVD-104," stated David Callanan, MD, Chief Medical Officer of Aviceda Therapeutics. "We believe AVD-104 is poised to address critical gaps in current GA therapies that limit adoption, such as the lack of functional vision benefit and the safety limitations of neovascular AMD conversion."

The Path Forward: A Renewed Commitment to Patients

Armed with these compelling results, Aviceda Therapeutics is not scaling back. Instead, the company is doubling down on its commitment to the GA community. It plans to advance AVD-104 into two large-scale Phase 3 confirmatory studies, which will be designed to definitively prove the drug's efficacy and safety against a sham (placebo) control. These trials, expected to begin in 2026, will incorporate the learnings from the Phase 2b study, ensuring that baseline patient characteristics are carefully balanced to provide the clearest possible picture of the drug's benefits.

The journey of AVD-104 is a powerful reminder that in the service of patient wellbeing, progress is not always linear. Sometimes, the most impactful innovations are found by looking beyond the primary headline and focusing on what truly matters: delivering tangible, life-changing benefits to those who need them most. For the millions affected by geographic atrophy, the prospect of a treatment that not only slows their disease but may also improve their sight and offer a superior safety profile represents a significant and welcome evolution in their care.